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Background: Although morbidity and mortality due to 
CAP remain important concerns in HIV+ patients, 
prognostic markers and outcome evaluation criteria have 
not been studied in ad hoc studies so far. The aim of the 
present study is to identify standard definitions for 
clinical course severity of CAP (clinical stabilisation 
and its timing) for simple, reproducible and validated 
outcome indicators and for clinical management, which 
could help establish a common ground for future clinical 
trials. 
Methods: A multicentric, observational, cohort, pro- 
spective study involving 40 Italian Centers of Infectious 
Diseases started on June 2000, is ongoing. Inclusion 
criteria are HIV infection and a suspected or confirmed 
CAP Assessments were performed at admission (base- 
line), during hospital stay, and 30 days after discharge. 
Clinical stability was defined as systolic blood pressure 
>90mmHg, pulse <90/min, respiratory rate (ReR) 
<20/min, 02 saturation >94%, temperature <37”C, 
spontaneous feeding, and normal mental status. Time-to- 
stability was censored at death for pts who never 
stabilised. 
Results: Among 448 patients enrolled, 416 not stable at 
baseline were evaluated for clinical stability. 341416 
(8.17%) never stabilised during hospital stay and 28/34 
died. For patients reaching clinical stability, only 2 
(0.53%, 95% CI 0.09-1.63%) relapsed after stabilisation, 
and none died. Median time-to-stability was 6 days (5- 
95 %I? 2-21). At multivariate Cox regression analysis, 
factors associated with failure to stabilise were CD4 
<2OO/mmc in the previous three months (RR=1.4, 
p=O.O02), pleural effusion (RR=1.9, p=O.OOS), 02 
saturation ~95% (RR=1.5, p=O.O14), ReR >25 
(RR=1.5, p=O.O15). Median discharge time was 10 days 
(5-95%‘“: 3-33). H owever, 29 pts who developed non- 
pulmonary complications were excluded. 
Conclusions: Definition of clinical stability appears a 
reliable tool for the management of HIV patients with 
CAP, and could be assessed in prospective studies as a 
predictor for outcome. Drug choice, length of treatment, 
and highly cost-effective therapeutic procedures, such as 
switch therapy, could be driven in the future by clinical 
stability. Most patients appeared to stay in hospital 
several days after reaching stability, with low rates of 
relapse, suggesting that length of stay could be safely 
shortened, reducing costs of care. 
Animal models and the correlates of protection 
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1. Animal models of HIV immunology 
Until recently, models for HIV have been of limited 
value. HIV-l infects chimpanzees and gibbons and HIV- 
2 infects a number of African and Asian monkeys but 
neither immunodeficiency nor disease results. The use of 
these models will be limited to vaccine testing with final 
testing of potential HIV vaccines likely to be done in 
chimpanzees. 
Rabbits show minor abnormalities of immune 
function associated with low-level persistent HIV-l 
infection but do not develop an AIDS-like disease. 
“Humanised” mice (severe immunodeficient mice 
reconstituted with human lymphoid cells) develop 
immune deficiency after infection with HIV-l but, as 
with the rabbit model, the value of HIV immunological 
research appears limited. 
Infection in cats with the T lymphotropic lentivirus, 
feline immunodeficiency virus (FIV), provides a small 
animal model with some clinical features relevant to 
AIDS and useful for screening therapies where a large 
number of animals is required. 
Simian immunodeficiency virus (SIV) has marked 
sequence homology with HIV (particularly HIV-2) and 
similar tropism for CD4 positive cells. Strains have been 
isolated from a wide range pf non-human primates. 
Two, SIV mat and SIV sm, produce in Asian macaque 
monkeys a disease remarkably similar to human HIV 
disease, including a similar seroconversion illness, 
subsequent lymphadenopathy (with similar histology) 
and steady decline over months to years in CD4 count 
and T cell responsiveness leading to wasting, oppor- 
tunistic infections (including CMV, PCP and Myco- 
bacterium avium complex), encephalitis and lymphoma. 
It is likely to be exploited for studies of immunopatho- 
genesis as well as therapy. 
2.Objective/Aim 
For study of the protective immune response to the virus 
and the immunopathogenesis of the disease. 
3. Method 
Random sampling among simian and rabbits with test 
soluble CD4. 
4. Result 
The decline in CD4 T helper cell number and function 
is multifactorial and not simply due to a direct affect of 
the virus. 
5. Conclusion 
The rapid expansion of knowledge from animal models 
should lead to major advances in therapy in the near 
future aimed at long term survival. 
